Dallas. Texas (PRWEB) July 16, 2013
“Next Generation Sequencing: Emerging Clinical Applications and Global Markets” Report Highlights -
This report provides:
Study Goals and Objectives
The goal of this study is to provide an in-depth analysis of the clinical next generation sequencing (NGS) industry (http://www.reportsnreports.com/reports/265829-next-generation-sequencing-emerging-clinical-applications-and-global-markets.html) , an emerging industry with enormous market potential. The approach of analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key indications where NGS diagnostics will have market share by 2018.
This report examines the markets for NGS diagnostics for the years 2012, 2013 and 2018.
The global NGS diagnostic markets are characterized and quantified by disease indication, test complexity, test purpose and geography.
Market segments that provide exciting growth opportunities include cancer, rare genetic diseases and prenatal screening.
The report provides a comprehensive discussion of NGS technologies, clinical applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for clinical genetic testing.
Reasons for Doing the Study
The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome.
The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies).
Beginning in 2005, the launch of next generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests.
As a result, opportunities emerged in clinical applications that are currently reaching fruition. The NGS clinical market is still relatively young and emerging, yet it holds great commercial promise.
Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. Several molecular genetic tests that have been successful on non-NGS formats will run on NGS platforms in the future.
At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential.
These technical and market factors are driving this market so that in 2013, it is timely to examine the clinical segment of the sequencing industry.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=265829. Alternatively can get DISCOUNT @ http://www.reportsnreports.com/contacts/discount.aspx?name=265829.
Scope and Format
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2012, 2013 and 2018.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed.
The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, common diseases, and pre- and post-natal screening.
Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world.
Market data covers the years 2012, 2013 and 2018.
Industry sectors analyzed include NGS instruments, target enrichment, informatics, clinical laboratories and the prenatal screening industry.
More than 110 companies in the clinical NGS industry are profiled in this report.
Explore more reports @ http://www.reportsnreports.com/market-research/biotechnology/.
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.
Read the full story at http://www.prweb.com/releases/clinical-next-generation/sequencing-ngs-market/prweb10931917.htm.
Copyright©2012 Vocus, Inc.
All rights reserved